Antisense Therapeutics Limited Stock Fundamentals
Antisense Therapeutics Limited fundamentals help investors to digest information that contributes to Antisense Therapeutics' financial success or failures. It also enables traders to predict the movement of Antisense Pink Sheet. The fundamental analysis module provides a way to measure Antisense Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Antisense Therapeutics pink sheet.
Antisense |
Antisense Therapeutics Limited Company Shares Outstanding Analysis
Antisense Therapeutics' Outstanding Shares are shares of common stock of a public company that were purchased by investors after they were authorized and issued by the company to the public. Outstanding Shares are typically reported on fully diluted basis, including exotic instruments such as options, or convertibles bonds.
Current Antisense Therapeutics Shares Outstanding | 669.04 M |
Most of Antisense Therapeutics' fundamental indicators, such as Shares Outstanding, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Antisense Therapeutics Limited is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Outstanding shares that are stated on company Balance Sheet are used when calculating many important valuation and performance indicators including Return on Equity, Market Cap, EPS and many others.
CompetitionBased on the latest financial disclosure, Antisense Therapeutics Limited has 669.04 M of shares currently outstending. This is 270.59% higher than that of the Healthcare sector and significantly higher than that of the Drug Manufacturers—Specialty & Generic industry. The shares outstanding for all United States stocks is 17.0% lower than that of the firm.
Antisense Therapeutics Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Antisense Therapeutics's current stock value. Our valuation model uses many indicators to compare Antisense Therapeutics value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Antisense Therapeutics competition to find correlations between indicators driving Antisense Therapeutics's intrinsic value. More Info.Antisense Therapeutics Limited is rated fourth in return on equity category among its peers. It is rated below average in return on asset category among its peers . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Antisense Therapeutics' earnings, one of the primary drivers of an investment's value.Antisense Shares Outstanding Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Antisense Therapeutics' direct or indirect competition against its Shares Outstanding to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of Antisense Therapeutics could also be used in its relative valuation, which is a method of valuing Antisense Therapeutics by comparing valuation metrics of similar companies.Antisense Therapeutics is currently under evaluation in shares outstanding category among its peers.
Antisense Fundamentals
| Return On Equity | -0.43 | |||
| Return On Asset | -0.25 | |||
| Operating Margin | (3.28) % | |||
| Current Valuation | 27.82 M | |||
| Shares Outstanding | 669.04 M | |||
| Shares Owned By Insiders | 19.30 % | |||
| Shares Owned By Institutions | 4.93 % | |||
| Price To Earning | (3.62) X | |||
| Price To Book | 3.05 X | |||
| Price To Sales | 24.46 X | |||
| Revenue | 1.78 M | |||
| Gross Profit | 1.71 M | |||
| EBITDA | (7.52 M) | |||
| Net Income | (5.81 M) | |||
| Cash And Equivalents | 19.23 M | |||
| Cash Per Share | 0.03 X | |||
| Total Debt | 227.4 K | |||
| Debt To Equity | 0.01 % | |||
| Current Ratio | 19.14 X | |||
| Book Value Per Share | 0.03 X | |||
| Cash Flow From Operations | (7.81 M) | |||
| Earnings Per Share | (0.01) X | |||
| Number Of Employees | 12 | |||
| Beta | 0.67 | |||
| Market Capitalization | 41.78 M | |||
| Total Asset | 22.44 M | |||
| Retained Earnings | (53 M) | |||
| Working Capital | 4 M | |||
| Current Asset | 5 M | |||
| Current Liabilities | 1000 K | |||
| Net Asset | 22.44 M |
Currently Active Assets on Macroaxis
Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in inflation. You can also try the Crypto Correlations module to use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins.
Other Consideration for investing in Antisense Pink Sheet
If you are still planning to invest in Antisense Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Antisense Therapeutics' history and understand the potential risks before investing.
| Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
| Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
| Transaction History View history of all your transactions and understand their impact on performance | |
| Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes | |
| Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope |